ClinicalTrials.gg
RecruitingNCT06298630Updated Jul 21, 2026

Long-term Follow-up Study of BRL-101 for TDT

An observational study in Thalassemia, Beta, sponsored by Bioray Laboratories. Recruiting at 7 sites in China. Open to participants aged 3 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Bioray Laboratories · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
45
Ages
3 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.

Planned enrollment
7th of 10
45 · median 96
Started
2024
with 10 others
Observational
10 of 44
8 open now
Primary completion
2038-08
later than 22 of 24 live
Registered
33rd of 44
by date
Lead sponsor
6 of 44
Bioray Laboratories

Among the 44 studies in beta-Thalassemia with a site in China, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 11 that started in 2024, is one of 10 observational ones, reaches primary completion later than 22 of the 24 other live ones, and was the 33rd registered.

beta-Thalassemia

295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 3 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in beta-Thalassemia with a site in China, or all of them as a file.
02

Study summary

Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.

Read the detailed description

Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.

03

Conditions studied

  • Thalassemia, Beta

Browse trials for

04

Who can participate

Ages eligible
3 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with transfusion-dependent β-thalassemia who have been treated with BRL-101.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
  2. Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.

Exclusion criteria

Exclusion Criteria:

- There are no exclusion criteria for this study

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No

Groups and cohorts

  • BRL-101

    All patients who have received BRL-101

    Other: Assessments

Interventions

  • OtherAssessments

    Safety and efficacy assessments

06

What researchers measure

Primary outcomes

  1. Incidence of hematologic malignancies

    Such as new lymphoma, leukemia, MDS, etc.

    Time frame: Up to 15 years post-drug product infusion

  2. Frequency, grade, and relationship of SAEs

    Frequency, grade, and relationship to BRL-101 of SAEs following BRL-101 reinfusion.

    Time frame: Within 2 years to 5years after BRL-101 Infusion

07

Study locations

3 of 7 sites recruiting
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong 510006, China
    Active, not recruiting

    Not enrolling at this site.

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Guangzhou, Guangdong 510006, China
    Not yet recruiting
    • Jianpei Fang, phD · Contact
  • Shenzhen Children 's Hospital
    Shenzhen, Guangdong 510006, China
    Not yet recruiting
    • Sixi Liu, phD · Contact
  • No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital
    Nanning, Guangxi 530021, China
    Not yet recruiting
    • Xinhua Zhang, phD · Contact
  • Xiangya Hospital of Central South University
    Changsha, Hunan 510510, China
    Recruiting
    • Bin Fu, PhD · Contact
  • Tianjin Institute of Hematology
    Tianjin, Tianjin Municipality 300000, China
    Recruiting
    • Jun shi, PhD · Contact
  • The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY
    Guangxi, 530021, China
    Recruiting
    • Yongrong Lai, PhD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Aug 2038, 164 months after the start.

Of 29 observational studies under beta-Thalassemia, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 156. This study's planned 164 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 7, 2024
StartActual
Dec 8, 2024
Primary completionEst.
Aug 20, 2038
CompletionEst.
Oct 15, 2038
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06298630
Collaborators
First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, Shenzhen Children's Hospital
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Dec 8, 2024
Primary completion
Aug 20, 2038 (estimated)
Completion
Oct 15, 2038 (estimated)
Last update
Jul 21, 2026

Study contacts

Rongmei Liang, phD
Contact
rongmeiliang@brlmed.com
021-64340008
Rongmei Liang, PhD
study chair · Bioray Laboratories

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion